Targeted Inhibition of Kinases in Cancer Therapy

Overview

Journal Mt Sinai J Med

Specialty General Medicine

Date 2010 Nov 25

PMID 21105121

Citations 18

Authors

Stacey J Baker

E Premkumar Reddy

Affiliations

Soon will be listed here.

Abstract

With an understanding of the molecular changes that accompany cell transformation, cancer drug discovery has undergone a dramatic change in the past few years. Whereas most of the emphasis in the past has been placed on developing drugs that induce cell death based on mechanisms that do not discriminate between normal and tumor cells, recent strategies have emphasized targeting specific mechanisms that have gone awry in tumor cells. However, the identification of cancer-associated mutations in oncogenes and their amplification in tumors has suggested that inhibitors against such proteins might represent attractive substrates for targeted therapy. In the clinic, the success of imatinib (Gleevec®, STI571) and trastuzumab (Herceptin®), both firsts of their kind, spurred further development of new, second-generation drugs that target kinases in cancer. This review highlights a few important examples each of these types of therapies, along with some newer agents that are in various stages of development. Second-generation kinase inhibitors aimed at overriding emerging resistance to these therapies are also discussed.

Citing Articles

Synthesis of novel spirochromane incorporating Schiff's bases, potential antiproliferative activity, and dual EGFR/HER2 inhibition: Cell cycle analysis and study.

Othman D, Hamdi A, Elhusseiny W, El-Azab A, Bakheit A, Hefnawy M Saudi Pharm J. 2023; 31(11):101803.

PMID: 37860686 PMC: 10582582. DOI: 10.1016/j.jsps.2023.101803.

Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.

Madanat L, Gupta R, Weber P, Kumar N, Chandra R, Ahaneku H Curr Cardiol Rev. 2022; 19(3):e310522205428.

PMID: 35642110 PMC: 10280990. DOI: 10.2174/1573403X18666220531094800.

Synthesis of some quinazolinones inspired from the natural alkaloid Lnorephedrine as EGFR inhibitors and radiosensitizers.

Ghorab M, Abdel-Kader M, Alqahtani A, Soliman A J Enzyme Inhib Med Chem. 2020; 36(1):218-237.

PMID: 33357002 PMC: 7781899. DOI: 10.1080/14756366.2020.1854243.

Discovery of 12O-A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor.

Fan Y, Huang Z, Wang X, Ma Y, Li Y, Yang S Molecules. 2020; 25(21).

PMID: 33182255 PMC: 7664879. DOI: 10.3390/molecules25215199.

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield.

Jo Y, Ali L, Shim J, Lee B, Hong C Cancers (Basel). 2020; 12(8).

PMID: 32731404 PMC: 7464778. DOI: 10.3390/cancers12082087.

References

Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G . Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985; 315(6022):758-61. DOI: 10.1038/315758a0. View

Mashkani B, Griffith R, Ashman L . Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem. 2010; 18(5):1789-97. DOI: 10.1016/j.bmc.2010.01.056. View

Schindler T, Bornmann W, Pellicena P, Miller W, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289(5486):1938-42. DOI: 10.1126/science.289.5486.1938. View

Ono M, Kuwano M . Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006; 12(24):7242-51. DOI: 10.1158/1078-0432.CCR-06-0646. View

Zhang J, Adrian F, Jahnke W, Cowan-Jacob S, Li A, Iacob R . Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010; 463(7280):501-6. PMC: 2901986. DOI: 10.1038/nature08675. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Wakeling A, Guy S, Woodburn J, Ashton S, Curry B, Barker A . ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002; 62(20):5749-54. View

Apperley J . Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(12):1116-1128. DOI: 10.1016/S1470-2045(07)70379-0. View

Quintas-Cardama A, Cortes J . Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008; 14(14):4392-9. DOI: 10.1158/1078-0432.CCR-08-0117. View

10.

Bareschino M, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F . Erlotinib in cancer treatment. Ann Oncol. 2007; 18 Suppl 6:vi35-41. DOI: 10.1093/annonc/mdm222. View

11.

Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-80. DOI: 10.1126/science.1062538. View

12.

Burgess M, Skaggs B, Shah N, Lee F, Sawyers C . Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005; 102(9):3395-400. PMC: 552942. DOI: 10.1073/pnas.0409770102. View

13.

Quintas-Cardama A, Kantarjian H, Cortes J . Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007; 6(10):834-48. DOI: 10.1038/nrd2324. View

14.

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

15.

Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A . Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007; 21(5):926-35. DOI: 10.1038/sj.leu.2404609. View

16.

Shah N, Skaggs B, Branford S, Hughes T, Nicoll J, Paquette R . Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007; 117(9):2562-9. PMC: 1940237. DOI: 10.1172/JCI30890. View

17.

Riely G, Pao W, Pham D, Li A, Rizvi N, Venkatraman E . Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 Pt 1):839-44. DOI: 10.1158/1078-0432.CCR-05-1846. View

18.

Gridelli C, Bareschino M, Schettino C, Rossi A, Maione P, Ciardiello F . Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007; 12(7):840-9. DOI: 10.1634/theoncologist.12-7-840. View

19.

Di Fiore P, PIERCE J, Fleming T, Hazan R, Ullrich A, King C . Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987; 51(6):1063-70. DOI: 10.1016/0092-8674(87)90592-7. View

20.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View